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Abstract 
Cancer is one of the major diseases causing worldwide death of human, related to some different 
epigenetic dysregulation.  Pancreatic ductal adenocarcinoma (PDAC) is a highly lethal cancer due 
to its rapid clinical progression & resistance to therapies. Recently, PDAC incidences have risen, 
while 5-year overall survival is about 6%. A primary complicating factor is the remarkable 
genetic and epigenetic heterogeneity of pancreatic cancer. Vividly, these highly variable 
alterations also define a core set of twelve signaling pathways along with cellular processes in 
most of PDAC tumors, including Wnt signaling also. One of the major dysregulation is 
overexpression of Wnt Proteins. There are 19 set of Wnt proteins found. In this project, novel 
IWP-2 inhibitor will focus a new light on cancer therapy. The findings indicate that WNT7B can 
serve as a primary determinant of differential Wnt/b-catenin activation in PDAC. Thereby, 
disrupting the interaction between Wnt ligands and their receptors may be suitable approach for 
therapeutic modulation of Wnt/b-catenin signaling in PDAC and other cancer contexts where the 
Wnt activation is mediated through ligand expression rather than mutations in members of 
canonical pathway. 
 
 
 
 
  
 
 
 
 
2 
 
 
 
 
 
CHAPTER 1 
INTRODUCTION 
 
 
 
 
 
 
 
 
 
 
3 
 
Introduction 
 
Cancer is a disease where there is abnormal cell division without control and these cells invade 
other tissues. Cancer cells can spread to other parts of the body through the blood and lymph 
systems. There are more than 100 different types of cancer. Most cancers are named for the organ 
or type of cell in which they start. For example, cancer that begins in the colon is called colon 
cancer; cancer that begins in melanocytes of the skin is called melanoma and the cancers that 
affect pancreatic system are known as Pancreatic Ductal Adenomacarcinoma. Cancer is often 
identified at a later phase. Therefore removing tumor or the organ by surgery is a tedious task. A 
report from the nation's leading cancer organization, National Cancer Institute shows that rates of 
death in the United States in 2014. There are 1,665,540 (does not include non-melanoma skin 
cancers) new cases for cancer with 585,720 deaths. 
 
Pancreatic ductal adenocarcinoma (PDAC) is the most usual type of pancreatic malignancy. 
PDAC is different from other cancers because of the biological barrier the tumor forms around 
itself. Pancreatic cancer is known to be the fourth leading cancer killer in the USA. Altogether, 
just 6% of patients survive 5 years after diagnosis is done. In the year 2012, it has been estimated 
that there will be 43,920 new diagnoses of pancreatic cancer and 37,390 deaths will attribute due 
it. Patients whose disease is recognized at an early period have a better scope of survival for long 
term. Currently there are no early detection tests available for this PDAC. In such cancer, pain 
occurs in the upper part of abdomen which radiates typically to the back as observed in tail of the 
pancreas or carcinoma of the body. Also there is poor appetite or nausea along with severe 
vomiting. Some others symptoms include significant weight loss as well as Diarrohea with loose 
stools. It generally obstructs the common bile duct as it runs through the pancreas. Also it can 
cause pale colored stool [3]. Over 30 years, NCI-supported laboratory scientists have been 
studying a gene known as KRAS (Kirsten rat sarcoma viral oncogene homolog), the genetic 
driver of pancreatic cancer initiation and propagation. However, presently no therapeutic 
solutions to KRAS mutations have been developed. Since the death rate are significant, the 
identification of risk factors & genetic changes, achieving more understanding of the metastatic 
process, developing better procedures of early detection and treatment offer are the means of 
better reducing PDAC [1]. 
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KRAS: The KRAS gene belongs to a class of genes known as oncogenes. When mutated, 
oncogenes have the prospective to cause normal cells to convert cancerous. The KRAS gene is in 
the Ras family of oncogenes, which also comprises two other genes: HRAS and NRAS. The 
proteins formed from these three genes are GTPases. These proteins play significant roles in cell 
differentiation, cell division, and the self-destruction of cells (apoptosis). The KRAS gene delivers 
instructions for making a protein called K-Ras that is involved primarily in regulating cell 
division. As part of a signaling pathway known as the RAS/MAPK pathway, the protein relays 
signals from outside the cell to the cell's nucleus. These signals instruct the cell to grow and 
divide or to mature and take on specialized functions (differentiate). The K-Ras protein is a 
GTPase, which means it converts a molecule called GTP into another molecule called GDP. The 
K-Ras protein acts like a switch, and it is turned on and off by the GTP and GDP molecules. To 
transmit signals, the K-Ras protein must be turned on by attaching (binding) to a molecule of 
GTP. The K-Ras protein is turned off (inactivated) when it converts the GTP to GDP. When the 
protein is bound to GDP, it does not relay signals to the cell's nucleus [2]. 
 
Objective 
1. To study about Wnt Canonical Pathway and overexpression of different Wnt protein in 
different cancers. 
2. To find the inhibitors for the specific target protein i.e. Wnt 7B responsible for Pancreatic 
Ductal Adenomacarcinoma. 
3. To carry out molecular docking of inhibitors with Wnt 7B as target protein and assessing 
binding affinity. 
4. To study the interacting residues as well as the interacting bonds between of Wnt7B and 
the docked inhibitors. 
5. To asses toxicity of the small inhibitor molecules. 
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Wnt Signaling Pathway 
 
The Wnt signaling pathways are assembly of signal transduction paths prepared of proteins that 
makes the signals flow from outside to inside of a cell over cell surface receptors. Signaling is a 
way of the system communication among living cells by processing biological information that 
governs basic cellular activities and co-ordinate cell actions. The signals are transmitted through 
signaling molecules, and this process ends up with altering of gene transcription in the nucleus 
resulting in many cellular processes such as differentiation and proliferation. Following three Wnt 
signaling pathways are considered: a) the Canonical Wnt pathway; b) the Non-canonical planar 
cell polarity pathway; c) the non-canonical Wnt or Calcium pathway. All 3 Wnt signaling 
pathways are stimulated because of the binding of a Wnt ligand with a Frizzled family receptor 
that permits the biological signal to the protein Dsh in the interior of cell [4]. 
 
The pathway named Canonical Wnt causes regulation of gene transcript; the non-canonical planar 
cell polarity pathway controls the cytoskeleton which is accountable for the shaping of the cell, 
and non-canonical Calcium inside the cell is controlled by Wnt/calcium pathway. Wnt signaling 
pathways practice either nearby cell-cell communication (paracrine) or through same-cell 
communication (autocrine). They are greatly evolutionarily conserved, which means they are 
parallel across many species i.e. from small bugs to humans. Clinical significance of Wnt 
signaling pathway has been established by changes that lead to a variety of diseases, counting 
breast and prostrate cancer, glioblastoma, type II diabetes and many more [4]. 
 
Canonical Wnt Pathway: Generally, vital difference between Canonical Wnt pathway and 
Non-canonical is that a canonical pathway includes the protein -catenin whereas a non-canonical 
pathway works self-sufficiently. A hallmark of Canonical Wnt signaling pathway activation is the 
enhanced level of cytoplasmic β-catenin protein. Stabilization of cellular β-catenin, leading to 
elevated protein levels and constitutive gene activation, has been supposed as an important step in 
many human cancers [4]. Although during the last few years several novel molecular data have 
contributed to the understanding of the complexity of the Wnt signaling pathway, many of the 
underlying mechanisms still remain unknown. Both genetic, epigenetic and expression alterations 
of molecules in the Wnt signaling pathway are characteristic for human solid tumors. Therefore, a 
future perspective, when it comes to anti-cancer therapeutics, 
would be to block the β-catenin-Tcf complex and thereby transcription of Wnt target genes[2]. 
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Mechanisms: The Canonical Wnt pathway (or Wnt/ -catenin pathway) is the Wnt pathway 
which reasons a gathering of -catenin within the cytoplasm along with its ultimate translocation 
into the nucleus acting as a transcriptional co-activator of transcription factors that fit with the T-
cell Factor and Lymphoid Enhancing factor family.  In case, there is no Wnt signaling, the -
catenin will not collect in the cytoplasm as a destruction complex would generally degrade it. 
This degradation complex comprises proteins which are: a) Adenomatosis Polyposis Coli (APC), 
b) Axin, c) protein Phosphatase 2A (PP2A), d) Casein Kinase 1  and, e) Glycogen Synthase 
Kinase 3 (GSK3). It cuts down -catenin by directing it for ubiquitination, which then sends it to 
the proteasome to get digested [5]. 
 
 
Figure 1. Wnt signaling in cancer [2]. 
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1. In case, the Wnt fixes Fz and LRP-5/6, this leads to the disruption of destruction complex 
function. It is because of the translocation of both the destruction complex to the plasma 
membrane caused by Wnt and a negative regulator of Axin. 
2. The negative regulator grows regionally in the cytoplasmic tail of LRP- 5/6. 
Phosphorylation due to other proteins in the destruction complex afterwards combines this 
tail to the Axin. 
3. Axin converts de-phosphorylated, its stability along with levels are diminished.  
4. The Dsh turn into activated through phosphorylation and its DIX and PDZ domains 
prevent the GSK3 activity of the destruction complex.  
5. This permits β-catenin to gather and confine to the nucleus and afterwards bring a cellular 
response through gene transduction beside the TCF/LEF transcription factors.   
 
Therapeutic Approach by targeting Wnt/-catenin Signaling Pathway: The main 
target of all these strategies is to check the -catenin translocation to nucleus or inhibits its 
expression or enhances its proteosomal degradation process and thus prevent the expression of 
Wnt target genes. Some of the approaches includes: i) DKK proteins as anticancer drugs; ii) 
Regulation at the protein level; iii) Activation of the proteosomal degradation process of -
catenin; iv) Reducing the sign of -catenin by RNA interference and antisense [6]. 
 
Inhibitors of Wnt Signaling: 
i. Wnt inhibitory factor 1 (WIF-1): It is a extracellular factor which is soluble, binds to 
Wnt and stops it from interacting with the frizzled receptor. 
ii. Secreted frizzled-related protein (sFRP): It is a inhibitor which is soluble, binds to Wnt 
and stops it from associating with the frizzled receptor. 
iii. Dickkopf (Dkk): Kremen & the lipoprotein receptor-related protein (LRP) co-receptor 
LRP5/6 binds to it and causes the complex to develop internally. Thus, inactivating the 
Wnt signaling pathway. 
iv. Sclerostin (SOST): Wnt signaling is inhibited by it through binding to the lipoprotein 
receptor-related protein (LRP) co-receptor LRP5/6. Osteoclasts produces it for inhibiting 
the differentiating and proliferation of osteoblasts. 
Wnt signaling pathway generally acts by switching off the GSK-3- dependent degradation 
pathway, thereby making -catenin to collect in the cytosol and thus to translocate in the nucleus 
to active transcription of the Wnt target Genes. 
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Wnt proteins in Various Cancer: The Wnts are secreted glycoproteins & generally 
comprise a large family of nineteen proteins in human beings thereby hinting to a daunting 
complexity of signaling regulation, function and biological outputs. Generally, Wnt proteins 
regulate a dizzying array of cellular processes which include cell fate determination, primary axis 
formation, motility and organogenesis and in recent researches; this pathway has been implicated 
in the stem cell renewal. Wnt signaling is the causative factor for a number of pleiotropic human 
pathologies. Most importantly, these pathologies include cancers of breast, skin and colon, 
skeleton defects & human birth defect disorders including most common human neural tube 
closure birth [8]. 
The Wnt4, Wnt5a and Wnt11 ligands also play a critical role in the early axis formation via the 
non-canonical, though recently Wnt11 has shown to play a critical role in the early axis 
formation. The activation of mutation of Canonical Wnt signaling pathway, ultimately lead to the 
stabilization and accumulation of B-Catenin in the nucleus of a cell. Actually, the mis-regulation 
of Wnt signal causes many development defects. Some of the Wnt proteins which are responsible 
for different cancers in human are: a) A proportion of human breast carcinomas express high 
levels of Wnt2, Wnt-5A, and Wnt-7B; b) Canonical Wnt signaling is only mediated when both 
the Fz and LRP are complexed with Wnt. Most of Wnt proteins can bind to multiple Fzs and vice 
versa, suggesting the redundancy in vivo; c) In PDAC cell lines, there is an overexpression of 
Wnt-7B and it serves as a primary determinant of differential Wnt/B-Catenin activation in the 
PDAC; d) It has been also found that gene expression profiling correlates an overexpression of 
Wnt-5A and the concomitant increase in the PKC activity with human melanoma progression [8]. 
 
Wnt7B: WNT7B is one of the members of Wnt gene family, which consists of structurally 
related genes and encoding the secreted signaling proteins. Wnt7B is expressed at high 
concentrations in the regions of active hyperplasia, metaplasia, and fibrotic change in the 
idiopathic pulmonary fibrosis patients. Pdgf signaling potentiates the Wnt2 (show WNT2 
Antibodies)-Wnt7B signaling for promoting the high levels of Wnt activity in mesenchymal 
progenitors which is required for proper development of endoderm-derived organs, like the lung. 
Wnt7B gene is a member of the WNT gene family, consisting of structurally related genes and 
encoding secreted signaling proteins. Such proteins have therefore been implicated in oncogenesis 
and in several other developmental processes, which includes regulation of cell fate and 
patterning, during the process of embryogenesis. Among other members of the human WNT 
family, this gene product is most likely to WNT7A protein. 
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IWP-2 (Inhibitor of Wnt Production-2) 
 
Figure 2. Structure of Inhibitor of Wnt Production-2 (from PubChem). 
Wnt signaling proteins are the minor secreted proteins which are dynamic in embryonic 
development, in tumor genesis and in tissue homeostasis. The Wnt proteins fix to receptors on the 
cell surface, thus beginning a signaling cascade which clues to β-catenin activation of gene 
transcription. IWP-2 is one of the inhibitor of Wnt production which impairs Wnt pathway 
activity in vitro with an IC value of 27 nM. IWP-2 also inactivates the Porcupine, a membrane 
bound O-acyltransferase which is accountable for palmitoylating Wnt proteins, again which is 
vital for their signaling ability and the discharge. At 5 μM, IWP-2 has shown to block Wnt-
dependent phosphorylation of frizzled co-receptor and the scaffold protein Dishevelled, prevents 
the accumulation of β-catenin. This compound has been therefore used to suppress embryonic 
stem cell self-renewal and thus decrease cancer cell migration, proliferation, & invasion. 
WLS ( Wntless Wnt Ligand Secretion mediator) 
 
Figure 3. Structure of Wntless Wnt Ligand Secretion mediator molecule (from PubChem). 
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WLS (Wntless Wnt ligand secretion mediator) is another protein-coding gene. Diseases that are 
associated with WLS include chronic intestinal vascular insufficiency, and the focal dermal 
hypoplasia, and among its related different super-pathways are Asparagine N-linked glycosylation 
and the Signaling through GPCR. GO annotations related to this gene include the Wnt-protein 
binding & the signal transducer activity. 
Canonical Wnt–β-catenin signaling in pancreatic ductal adencocarcinoma.  
 
 
            
Figure 4. Canonical Wnt–β-catenin signaling in Pancreatic Ductal Adencocarcinoma [8]. 
 
In normal development, canonical Wnt–β-catenin signaling rest on secreted ligands (Wnt ligands) 
that initiate receptors (Frizzled (Fzd)–Lrp complex) that chunk the proteosomal degradation of β-
catenin promoted by the destruction complex (comprising adeomatous polyposis coli (APC), 
glycogen synthase kinase 3β (GSK3β), axin, and other such proteins) through initiation of 
Dishevelled (Dvl). -catenin accumulation is habitually detected in pancreatic ductal 
adenocarcinoma (PDAC). Accumulated -catenin can translocate into the nucleus and initiate 
target genes in performance with T CF/LEF co-factors. Currently, the dominant mechanism of 
persistent -catenin accumulation and activity in PDAC is unclear. There is evidence for both 
autocrine (owing to epithelial-derived Wnt ligands) and cell-autonomous activation (through Gli 
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signaling and genes such as ataxia telangiectasia group D-associated (ATDC), which activates 
Dvl). There may also be assistances from the stromal cells and extracellular matrix that may 
encourage -catenin accumulation [8,9]. 
 
Bioinformatics & Computational Biology 
Very easy drug designing has been recently paved in drastic ways by the enhancement of 
Bioinformatics and Chemo-informatics. The potential to speed up drug discovery processes has 
been shown by Computational biology & Bioinformatics. This reduces the cost of the processes 
and thus changes the way of designing of drugs. The drug designing processes involving various 
methods of identifying novel compounds is facilitated and accelerated by the rational drug design. 
The docking of the drug molecule / ligand / inhibitor with the target is one such advanced method. 
The site of action is known as the site where the drug binds. This is ultimately responsible for the 
pharmaceutical effect in the target.  
Two molecules bind to each other in the 3D space by the method of Docking. The free enthalpy 
of the binding ligand is computed by the use of regression based or knowledge based scoring 
functions. Several tools, softwares & servers are available for calculations of docking. Docking 
may be rigid, flexible, & semi-flexible. Different databases are available to store macromolecular 
3D structure and ligand structure, extracted from NMR co-ordinates. These are used for 
simulations and docking. Computational biology or the In Silico approach is day by day 
developing in more refine manner. This has become a very promising field and with the help of 
this the time and cost of the biological work related to drug discovery, molecular interaction is 
reduced. 
 
 
 
 
 
 
 
13 
 
 
 
 
 
CHAPTER 3 
TOOLS and METHODS  
 
 
 
 
 
 
 
 
 
 
 
 
14 
 
TOOLS AND METHODS 
 
1. Computer Atlas of Surface Topology of Proteins (CASTp): It is a Bioinformatics 
tool which is an online reserve for identification of some geometric possessions of protein like 
delineating, locating, and thus computing concave surface regions on 3D structures of proteins 
attained from the PDB also to study the surface features, functional regions and an active site of 
proteins. Also, there are measurements of the number of mouth openings (of cavity or pocket), 
circumference of mouth lips (of void or pocket), area of the openings (of void or pocket), in 
together Molecular surface (MS) and Solvent Accessible (SA) of each of the pocket.                                                  
There can also be request calculation for a certain molecule. Either the results will be exposed on 
the screen or will be sent by email. The result which is sent by email includes measured 
parameters for cavities, pockets and mouth openings, along with the listing of wall atoms and the 
mouth atoms for separate pocket. Additionally, the PyMOL plugin which is downloadable helps 
in visualizing the pocket of our interest. 
2. Phyre and Phyre2 (Protein Homology/AnalogY Recognition Engine): These are web-based 
services for predicting the structure of protein that are allowed for the non-commercial usage. One 
of the maximum popular methods for the prediction of protein structure is Phyre cited over more 
than 1500 times. Other widely used methods like PSI-BLAST cannot generate reliable protein 
models whereas like other remote homology recognition techniques, it can regularly generate. A 
user-friendly interface is ensured for the users by the design of Phyre2 inexpert in predicting the 
structure of protein.  
3. PubMed: It is one such free search engine, which access primarily the abstracts on life 
sciences and different biomedical topic the MEDLINE database of references. The the database as 
part of the Entrez system of information retrieval is maintained by the United States National 
Library of Medicine (NLM) at the National Institutes of Health. Always free access is provided 
by this to Medline, NLM's database of citations and abstracts in the fields of medicine, nursing, 
dentistry, veterinary medicine, health care systems, and preclinical sciences. It links to the full-
text articles found in PubMed Central or at publisher web sites, and other related resources. 
Provides an Advanced search, with Clinical Queries search filters, and Special Queries pages. It 
links to the related articles and provides discovery tools for other data that may be of interest. It 
also includes an automatic e-mailing of search updates, the ability for saving records, and filtering 
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of search results using "My NCBI". It brings a spell checker feature and links to NCBI molecular 
biology resources. It provides a record for an article prior to being indexed with MeSH® and 
added to MEDLINE or converted to out-of-scope status.  
4. PubChem: It is a database consisting of chemical molecules with their activities against 
biological assays. National Center for Biotechnology Information (NCBI), which is a component 
of the National Library of Medicine maintains this system. This is a division of the United 
States National Institutes of Health (NIH). PubChem is accessible freely by a web user interface. 
FTP allows to download millions of compound structures and free descriptive datasets. This 
contains substance descriptions and small molecules with less than about thousand atoms and 
thousand bonds. More than eighty database vendors add to the growing PubChem database.
 
Website:- http://pubchem.ncbi.nlm.nih.gov.
 
5. OpenBabel GUI (file format converter): It is a chemical toolbox designed for speaking  many 
languages of chemical data. Basic operation: a) Chemical objects which are presently 
molecules or reactions are converted from one file format to some another by OpenBabel. 
An alternative for a command line is this interface having the capabilities which are same.  I) 
The type of the type of the input file is selected from the list which appears dropdown. II) 
The "..." button is clicked and then the file is selected where contents are shown. III) The file 
and the output format is chosen in a very same manner. The output can be just displayed 
without being saved by not selecting an output file or by checking "Output below only..". IV) 
The "Convert" button is clicked. The number of molecules converted is given in the message 
window which is below the button, and the contents of the output file are shown. If multiple 
molecules are allowed by the output format then all such molecules in an input file are 
converted by default. 
6. AutoDock: It is a suite of docking tools which are automated. Thereby designed for predicting 
how small molecules are, like drug candidates or substrates, fix to known 3D structure receptor. 
AutoDock Tools  is used for setting up and running AutoDock. It is a docking software which is 
automated and designed for predicting how molecules of small size, such as drug or substrates 
candidates generally fix to a known 3D structure receptor. 
7. UCSF Chimera: It is one of the greatly extensible programs for visualization in an interactive 
manner & analyzing structures of molecules and other information that includes density maps, 
sequence alignments supramolecular assemblies, trajectories, conformational ensembles and 
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docking results. Animations and images of high quality can be thereby generated. Chimera 
comprises several tutorials and complete documentation, and thus can be downloaded without any 
charge for a government, academic, non-profit, or personal use. Resource for Biocomputing, 
Visualization, and Informatics, developed Chimera and National Institutes of Health (NIGMS 
P41-GM103311) funded it. 
 
8. LigPlot+ v.1.4.5: It is a computer program which generates the schematic 2-D image of the 
docked protein–ligand complexes. The 3-D structure of the docked complex is the input in PDB 
file and the software produces their interacting residues and bonds. In the present study, LigPlot+ 
was used to identifying interacting residues as well as the interacting bonds between of Wnt7B 
and the docked inhibitors. 
 
9. The OSIRIS Property Explorer: It helps in drawing of chemical structures & calculation of 
various drug-relevant properties (solubility, Toxicity Risk Assessment, Molecular Weight, 
Overall Drug-Score, etc.) when a valid structure is given. The predicted results are thus color 
coded and valued. Also the high risk properties of any effects which are not desirable like 
mutagenicity or a poor intestinal absorption are shown in red color. On the other hand, drug-
conform behavior is indicated by a green color. 
The logP value of a compound, which is the logarithm of its partition coefficient between 
noctanol and water log(coctanol/cwater), is a well established measure of the compound's 
hydrophilicity. Low hydrophilicities and therefore high logP values cause poor absorption or 
permeation. It has been shown for compounds to have a reasonable probability of being well 
absorb their logP value must not be greater than 5.0. Optimizing compounds for high activity on a 
biological target almost often goes along with increased molecular weights. However, compounds 
with higher weights are less likely to be absorbed and therefore to ever reach the place of action. 
The drugs should have a molecular weight below 450. In druglikeness property a positive value 
for the chemicals states that the molecule contains predominantly fragments which are frequently 
present in commercial drugs. The drug score combines druglikeness, cLogP, molecular weight 
and toxicity risks in one handy value than may be used to judge the compound's overall potential 
to qualify for a drug. 
Drug score: It combines druglikeness, cLogP, logS, molecular weight and toxicity risks in one 
handy value than may be used to judge the compound's overall potential to qualify for a drug. 
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Steps For DOCKING using AutoDock Tools 
1. First of all the macromolecule 3D structure was downloaded in .pdb format. 
2. In case the structure was missing, “Phyre Server” tool was used. 
 The FASTA sequence was pasted in the dialog box. 
 The E-Mail ID was provided. 
 The Validated structure was generated and sent to mail ID. 
 
 
 
Figure 5. Windows for phyre server. 
3. The possible Wnt inhibitor molecules were searched using PubChem tools. The ligands’ 
similar structures were then downloaded. 
4. The ligands’ similar structures were then downloaded in .sdf format. 
    The downloaded .sdf format ligand was then, opened in Open Babel GUI software. 
    Here the .pdf format of the ligands was thus obtained. 
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STEPS in AutoDock Tools- 1.5.6rc3 
1. First the Opening the Wnt macromolecule downloaded. 
a. File > Read molecule > give .pdb file location. 
b. Edit > delete water >  
c. Edit > Add > Hydrogen > Polar Hydrogen 
d. Edit > Add > Kollman Charges 
e. Edit > Atoms > Assign AD4 type 
f. File > save > save as .pdbqt 
2. LIGAND 
a. Ligand > input > open (only .pbf file) 
b. Ligand > torsion tree > root to be chosen 
c. Ligand > torsion tree > root to be detected 
d. Ligand > output > save as .pdbqt 
 
3. GRID 
a. Grid > Macromolecule > chose (the protein) > select molecule 
b. Grid > set map type > choose the ligand > select ligand 
c. Grid > grid box (active site to be inhibited) – select the co-ordinate from .pdf file 
xyz. 
d. Centre > on named atom (using CastP) 
 
 
Figure 6. Windows for CastP. 
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Figure 7. Pocket information by CastP. 
Figure 8. Windows for Docking. 
e. Enter the full name of the atom 
f. File > close saving the current. 
g. Output > save .gpf 
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4. RUN 
a. Run > Run Autogrid >select the pathname for the program 
i. Browse > C:/ > program  (86) > The Scripps research Institute > Autogrid4 
ii. Give the parameter filename by choosing the .gpf file saved 
iii. Launch 
5. DOCKING 
a. Docking > Macromolecule > Rigid filename to be set > Macromolecule to be 
selected 
b. Docking >ligand > choose 
c. Docking > search parameter > Genetic Algorithm > accept 
d. Docking > output > Lamarckian GA (4.2) > save as .dpf file (automatically saved) 
6. RUN 
a. Run > Run AutoDock >select the pathname for the program 
i. Browse >C:/ > program  (86) > The Scripps research Institute > Autodock4 
ii. Give the parameter filename by choosing the .dlg file saved 
iii. Launch 
Here after few minutes, the docking gets completed. Analysis is done using a software tool know 
as Chimera. 
1. Open the .dlg file in wordpad. 
2. Now press Ctrl+F to search rmsd. 
3. Previous step, leaves to rmsd table which shows binding energy table. 
4. The residue number of least binding molecule was pasted in the protein molecule giving 
rise to the docked molecule.   
After this the ligand molecules were tested in Osiris Property Explorer for the Toxicity if any and 
henceforth using LigPlot+ v.1.4.5 for identifying interacting residues as well as the interacting 
bonds between Wnt7B and the docked complex. 
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Results for Docking with Ligand IWP-2 and its analogues 
 
Identifying binding sites of ATP on Wnt7B: The analysis for the identifying binding sites of 
ATP was performed using various software and online servers. Using CastP server, we obtained 
the possible ATP binding sites. The results obtained from this server showed that TRP215 was the 
interacting residue. CastP calculation was done for the validation of results. From CastP results, it 
was observed that TRP215 was found to be present in the largest binding pocket of Wnt7B. 
Further, the docking of   was performed with possible inhibitors.  
 
Docking of Wnt7B with its existing inhibitors: The docking studies were then carried out using 
Autodock 4.0 in order to obtain the binding energies upon interaction of the various existing 
drugs with Wnt7B. The experiment was thus carried out by docking various inhibitors on 
previously recognized ATP binding residue of   i.e. TRP215. The binding energies obtained from 
the above experiment are tabulated in Table 1. The results clearly showed that 2-[[3-(3,5-
dimethylphenyl)-4-oxo-6,7-dihydrothieno[3,2-d]pyrimidin-2-yl]sulfanyl]-N-(6-methyl-1,3-
benzothiazol-2-yl)acetamide demonstrates highest binding energy for all the three sites of ATP 
interaction. It showed the best binding energy at TRP215 (-7.05 kcal/mol) among all the possible 
inhibitors under the category of IWP-2. 
 
Table 1. Results for Docking with Ligand IWP-2 and its analogues. 
Sl. 
No. 
IUPAC Name of the ligand      
(IWP-2) 
Binding Energy 
in (kcal/mol) 
Docked Complex 
1 
2-[2-[(6-methyl-1,3-benzothiazol-
2-yl)amino]-2-oxoethyl]sulfanyl-
N-phenylacetamide 
-6.23 
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2 
2-[(3-cyclohexyl-6-methyl-4-oxo-
6,7-dihydrothieno[3,2-
d]pyrimidin-2-yl)sulfanyl]-N-(6-
methyl-1,3-benzothiazol-2-
yl)acetamide 
-5.11 
 
3 
2-[2-[(6-methyl-1,3-benzothiazol-
2-yl)amino]-2-oxoethyl]sulfanyl-
N-(4-methylphenyl)acetamide 
-6.51 
 
4 
 2-[6-amino-1-(4-methylphenyl)-
4-oxopyrimidin-2-yl]sulfanyl-N-
(6-methyl-1,3-benzothiazol-2-
yl)acetamide 
-5.82 
 
5 
 2-[[3-(3,5-dimethylphenyl)-4-
oxo-6,7-dihydrothieno[3,2-
d]pyrimidin-2-yl]sulfanyl]-N-(6-
methyl-1,3-benzothiazol-2-
yl)acetamide 
-7.05 
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6 
N-(6-methyl-1,3-benzothiazol-2-
yl)-2-[(7-oxo-5-phenyl-1H-
[1,2,4]triazolo[4,3-a]pyrimidin-3-
yl)sulfanyl]acetamide 
-5.84 
 
7 
2-(2-benzylsulfanyl-4-oxo-1H-
pyrimidin-6-yl)-N-(6-methyl-1,3-
benzothiazol-2-yl)acetamide 
-6.82 
 
8 
2-[[(6R)-3-ethyl-6-methyl-4-oxo-
6,7-dihydrothieno[3,2-
d]pyrimidin-2-yl]sulfanyl]-N-(6-
methyl-1,3-benzothiazol-2-
yl)acetamide 
-6.95 
 
9 
 N-(1,3-benzothiazol-2-yl)-2-
[[(6S)-3-benzyl-6-methyl-4-oxo-
6,7-dihydrothieno[3,2-
d]pyrimidin-2-
yl]sulfanyl]acetamide 
-6.29 
 
 
 
 
25 
 
Results for Docking with Ligand WLS and its analogues 
Similarly, the docking studies were then carried out using Autodock 4.0 in order to obtain the 
binding energies upon interaction of the WLS inhibitors with Wnt7B. The experiment was thus 
carried out by docking various inhibitors on previously recognized ATP binding residue of   i.e. 
TRP215. The binding energies obtained from the above experiment are tabulated in Table 2. The 
results clearly showed that the best binding energy of inhibitor in category of WLS is -5.25 
kcal/mol for 2-[2-[4-[(2-chloro-4-methylsulfonylphenyl)diazenyl]-3-methylphenyl]ethylamino] 
ethanol molecule. 
Table 2. Results for Docking with Ligand WLS and its analogues. 
Sl. 
No. 
IUPAC Name of the ligand (WLS) 
Binding Energy 
(kcal/mol) 
Docked Complex 
1 
 3-[2-[4-[(2-chloro-4-
methylsulfonylphenyl)diazenyl]-3-
methylphenyl] 
ethylamino]propanenitrile 
-5.19 
 
2 
2-[2-[4-[(2-chloro-4-
methylsulfonylphenyl)diazenyl]-3-
methylphenyl]ethylamino]ethanol 
-5.25 
 
  
LigPlot Analysis for IWP-2 amd its similar structures: 
Docked results were analyzed by LigPlot+ v.1.4.5 software. In the LigPlot analysis, generally the 
residues denoted by red coloured arc show the hydrophobic residues of Wnt7B interacting with 
the drug molecule. The red, black and blue colour spheres indicate the oxygen, carbon and 
nitrogen atoms, respectively, of the drug molecule whereas the purple coloured lines represent the 
bonds present within these drug molecule. The external bonds between the drug and Wnt7B are 
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represented by blue colour and the bonds which are coloured green indicate the hydrogen bonds 
that are formed between the drug and Wnt7B. It was then observed from Ligplot analysis that 
inhibitors interact with TRP215 which was previously validated by CastP. It further validated the 
assumption that TRP215 could be the ATP binding residues. 
 
2-[2-[(6-methyl-1,3-benzothiazol-2-
yl)amino]-2-oxoethyl]sulfanyl-N-
phenylacetamide
 
2-[(3-cyclohexyl-6-methyl-4-oxo-6,7-
dihydrothieno[3,2-d]pyrimidin-2-yl)sulfanyl]-N-(6-
methyl-1,3-benzothiazol-2-yl)acetamide 
 
2-[2-[(6-methyl-1,3-benzothiazol-2-
yl)amino]-2-oxoethyl]sulfanyl-N-(4-
methylphenyl)acetamide
 
 2-[6-amino-1-(4-methylphenyl)-4-
oxopyrimidin-2-yl]sulfanyl-N-(6-methyl-1,3-
benzothiazol-2-
yl)acetamide
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 2-[[3-(3,5-dimethylphenyl)-4-oxo-6,7-
dihydrothieno[3,2-d]pyrimidin-2-yl]sulfanyl]-
N-(6-methyl-1,3-benzothiazol-2-
yl)acetamide
 
N-(6-methyl-1,3-benzothiazol-2-yl)-2-[(7-oxo-5-
phenyl-1H-[1,2,4]triazolo[4,3-a]pyrimidin-3-
yl)sulfanyl]acetamide 
 
2-(2-benzylsulfanyl-4-oxo-1H-pyrimidin-6-yl)-N-(6-
methyl-1,3-benzothiazol-2-yl)acetamide 
 
2-[[(6R)-3-ethyl-6-methyl-4-oxo-6,7-
dihydrothieno[3,2-d]pyrimidin-2-yl]sulfanyl]-N-(6-
methyl-1,3-benzothiazol-2-yl)acetamide 
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 N-(1,3-benzothiazol-2-yl)-2-[[(6S)-3-benzyl-6-methyl-4-oxo-6,7-dihydrothieno[3,2-d]pyrimidin-2-
yl]sulfanyl]acetamide 
 
 
Figure 9. LigPlot Analysis for Inhibitor of Wnt Production-2 and its analogues. 
 
LigPlot Analysis for WLS and its analogues: 
 3-[2-[4-[(2-chloro-4-
methylsulfonylphenyl)diazenyl]-3-
methylphenyl]ethylamino]propanenitrile
 
2-[2-[4-[(2-chloro-4-
methylsulfonylphenyl)diazenyl]-3-
methylphenyl]ethylamino]ethanol  
 
 
Figure 10. LigPlot Analysis for WLS and its analogues. 
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Toxicity measure for IWP-2 ligand and its analogues using OSIRIS property 
calculator:  
The OSIRIS Property Explorer was used for measurement of various drug-relevant properties 
(Toxicity Risk Assessment, Molecular Weight, Overall Drug-Score, etc.) when a valid structure is 
given. The predicted results are thus color coded and valued. From the property prediction results, 
it was observed that the all the compounds have cLogP values less than 5. The logP value of a 
compound, which is the logarithm of its partition coefficient between noctanol and water 
log(coctanol/cwater), is a well established measure of the compound's hydrophilicity. Low 
hydrophilicities and therefore high logP values cause poor absorption or permeation. It has been 
shown for compounds to have a reasonable probability of being well absorb their logP value must 
not be greater than 5.0. Optimizing compounds for high activity on a biological target almost 
often goes along with increased molecular weights. 
However, compounds with higher weights are less likely to be absorbed and therefore to ever 
reach the place of action. So the molecular weight should be around 450g/mol. In druglikeness 
property a positive value for the chemicals states that the molecule contains predominantly 
fragments which are frequently present in commercial drugs. All the compounds had a positive 
value for the drug likeness. The drug score combines druglikeness, cLogP, molecular weight and 
toxicity risks in one handy value than may be used to judge the compound's overall potential to 
qualify for a drug. In case of IWP-2 and its analogues, all the compounds showed green color for 
all the toxic parameters. Also the high risk properties of any effects which are not desirable like 
mutagenicity or a poor intestinal absorption are shown in red color. On the other hand, drug-
conform behavior is indicated by a green color. All the IWP-2 ligands showed green color for risk 
to Mutagenicity and Tumorigenicity, which means they exhibit no toxicity. The molecule 2-[[3-
(3,5-dimethylphenyl)-4-oxo-6,7-dihydrothieno[3,2-d]pyrimidin-2-yl]sulfanyl]-N-(6-methyl-1,3-
benzothiazol-2-yl)acetamide, was detected to be, not toxic from the Table 3, below. 
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    Table 3.Toxicity measure for IWP-2 ligand and its analogues using ORISIS property calculator. 
Sl. 
No. 
IUPAC Name of 
the ligand (IWP-2) 
Binding 
Energy 
(kcal/mol) 
Drug 
Likeness 
Score 
Mol. 
Wt. 
(g/mol) 
cLogP 
Toxicity 
(Mutagenicity) 
Toxicity 
(Tumorigenicity) 
Drug 
Score 
1 
 
 
2-[2-[(6-methyl-
1,3-benzothiazol-
2-yl)amino]-2-
oxoethyl]sulfanyl-
N-
phenylacetamide 
 
 
-6.23 0.348 371 3.541 No No 0.428 
2 
2-[(3-cyclohexyl-6-
methyl-4-oxo-6,7-
dihydrothieno[3,2-
d]pyrimidin-2-
yl)sulfanyl]-N-(6-
methyl-1,3-
benzothiazol-2-
yl)acetamide 
-5.11 0.302 486 4.793 No No 0.221 
3 
 
 
2-[2-[(6-methyl-
1,3-benzothiazol-
2-yl)amino]-2-
oxoethyl]sulfanyl-
N-(4-
methylphenyl)acet
amide 
 
-6.51 0.436 385 3.885 No No 0.41 
4 
  
 
2-[6-amino-1-(4-
methylphenyl)-4-
oxopyrimidin-2-
yl]sulfanyl-N-(6-
methyl-1,3-
benzothiazol-2-
yl)acetamide 
 
 
-5.82 0.372 437 3.429 No No 0.286 
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5 
 2-[[3-(3,5-
dimethylphenyl)-4-
oxo-6,7-
dihydrothieno[3,2-
d]pyrimidin-2-
yl]sulfanyl]-N-(6-
methyl-1,3-
benzothiazol-2-
yl)acetamide 
-7.05 0.309 400 4.748 No No 0.257 
6 
N-(6-methyl-1,3-
benzothiazol-2-yl)-
2-[(7-oxo-5-
phenyl-1H-
[1,2,4]triazolo[4,3-
a]pyrimidin-3-
yl)sulfanyl]acetami
de 
-5.84 0.922 448 3.735 No No 0.427 
7 
2-(2-
benzylsulfanyl-4-
oxo-1H-pyrimidin-
6-yl)-N-(6-methyl-
1,3-benzothiazol-
2-yl)acetamide 
-6.82 0.036 422 3.656 No No 0.241 
8 
2-[[(6R)-3-ethyl-6-
methyl-4-oxo-6,7-
dihydrothieno[3,2-
d]pyrimidin-2-
yl]sulfanyl]-N-(6-
methyl-1,3-
benzothiazol-2-
yl)acetamide 
-6.95 0.995 432 3.644 No No 0.517 
9 
 N-(1,3-
benzothiazol-2-yl)-
2-[[(6S)-3-benzyl-6-
methyl-4-oxo-6,7-
dihydrothieno[3,2-
d]pyrimidin-2-
yl]sulfanyl]acetami
de 
-6.29 0.999 480 4.311 No No 0.397 
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Toxicity measure for WLS ligand and its analogues using OSIRIS property 
calculator:  The WLS ligands showed high risk (red color) to Mutagenicity and 
Tumorigenicity. They are toxic. So, IWP-2 ligands are less toxic than the WLS ligands on basis of 
Table 3 and Table 4 (below). 
Table 4. Toxicity measure for WLS ligand and its analogues using OSIRIS property calculator 
Results. 
Sl. 
No. 
IUPAC Name for 
WLS and its 
Analogues 
Binding 
Energy 
(kcal/mol) 
Score of 
Drug 
Likeness 
Mol. 
Wt. 
(g/mol) 
cLogP 
Toxicity 
(Mutagenicity) 
Toxicity 
(Tumorigenicity) 
Drug 
Score 
1 
 3-[2-[4-[(2-
chloro-4-
methylsulfonylphe
nyl)diazenyl]-3-
methylphenyl]eth
ylamino]propanen
itrile 
-5.19 0.007 406 2.922 Yes Yes 0.067 
2 
2-[2-[4-[(2-chloro-
4-
methylsulfonylphe
nyl)diazenyl]-3-
methylphenyl]eth
ylamino]ethanol 
-5.25 0.007 395 3.079 Yes Yes 0.063 
 
The role of Wnt7B inhibition in the treatment of Pancreatic Ductal Adenoma Carcinoma disease 
has been evident from various experiments and research carried out till date. Hence, various drugs 
have been developed which can inhibit Wnt7B by either blocking the ATP binding site, blocking 
the binding site for client proteins or by obstructing the dimerization site at the protein. The 
nucleotide binding to Wnt7B alters its conformation and defines the subset of chaperones with 
which it interacts. In the present study, we have attempted to locate the residues which are 
involved in the ATP binding site of domain and then blocking this site by various inhibitors and 
thereby to identify a novel inhibitor. 
Hence, through our experiments we attempted to identify the interacting residues of ATP binding 
site in Wnt7B and a potential inhibitor which can block the identified ATP binding site. The 
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binding site of the ATP is not known; hence we predicted the possible ATP binding sites present 
in this domain using various software. CastP server was used which showed TRP215 as the 
interacting residue between   and ATP. CastP calculation was carried out to validate the 
prediction. It was validated by CastP that TRP215 could be ATP interacting site in   as it is 
present in the largest binding pocket of the structure. This procedure was followed by a docking 
experiment between   with inhibitors. The docked results were analyzed using LigPlot+ v.1.4.5 to 
identify the interacting residues. It was observed that both ATP and the inhibitor interact with the 
previously determined ATP binding site of   i.e. TRP215. From this result, it was further validated 
that TRP215 could be the ATP interacting site on domain. 
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CHAPTER 5 
CONCLUSION 
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CONCLUSION 
From above in silco study we can conclude that IWP-2 shows inhibitory activity towards Wnt7B 
protein involved in overexpression of Pancreatic Ductal Carcinoma (PDAC) as it is interacting 
with the Tryptophan ion of active site and turn it into inactive form. This experiment is only the in 
silico approach, which need approval after future experiments (in vivo). We had tested two 
inhibitor including, IWP-2 and WLS against Wnt7B. If the docking results establish that these 
bioactive compounds have potent in vivo Wnt inhibition property and will add a new achievement 
in cancer treatment. 
Moreover, toxicity studies to be performed for establishing it as a safe and effective drug. The 
establishment of ATP binding site in   and determining the best inhibitor for Wnt7B could further 
lead to the effective blockage of Wnt7B which would ultimately causes degrading B-catenin for 
the treatment in Pancreatic Ductal Adenomacarcinoma disease. 
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